Last updated: August 27, 2026
Berotralstat dihydrochloride, marketed as Orladeyo by BioCryst Pharmaceuticals, is an oral, once-daily plasma kallikrein inhibitor for routine prevention of hereditary angioedema attacks. Its commercial position has strengthened rapidly since its U.S. launch in December 2020. Global Orladeyo revenue increased from approximately $66 million in 2021 to $349 million in 2023 and reached roughly $500 million in 2024, according to BioCryst disclosures.[1-4]
The product’s growth is driven by oral convenience, chronic-use positioning, expansion of treated patients, and increasing penetration outside the United States. Its main commercial constraints are competition from Takeda’s Takhzyro and C1 esterase inhibitor products, payer controls, the limited size of the hereditary angioedema market, and the eventual arrival of oral and injectable competitors.
What is berotralstat dihydrochloride and how is Orladeyo used?
Berotralstat dihydrochloride is the active pharmaceutical ingredient in Orladeyo. It inhibits plasma kallikrein, reducing bradykinin generation and preventing hereditary angioedema attacks.
| Attribute |
Berotralstat dihydrochloride |
| Brand |
Orladeyo |
| Company |
BioCryst Pharmaceuticals |
| Drug class |
Plasma kallikrein inhibitor |
| Administration |
Oral, once daily |
| U.S. indication |
Routine prophylaxis of hereditary angioedema attacks in adults and pediatric patients age 12 and older |
| U.S. approval |
December 3, 2020 |
| Standard adult dose |
150 mg once daily with food |
| Pediatric use |
Approved for patients age 12 and older under the original U.S. indication |
| Acute-attack use |
Not indicated for treatment of acute hereditary angioedema attacks |
The product differs from Takhzyro, which is administered subcutaneously, and from Haegarda, which requires subcutaneous C1 esterase inhibitor administration. The oral route reduces administration burden for patients who prefer to avoid injections or infusions.[5]
How large is the berotralstat and hereditary angioedema market?
The addressable market is a specialty orphan-drug market rather than a broad primary-care market. Hereditary angioedema affects a small patient population, but treatment is chronic, high value, and concentrated among specialty prescribers.
The principal market segments are:
- Long-term prophylaxis.
- On-demand treatment of acute attacks.
- Pediatric hereditary angioedema management.
- International markets with growing diagnosis and reimbursement.
- Patients switching from injectable prophylaxis to oral treatment.
BioCryst has stated that the global hereditary angioedema market includes tens of thousands of diagnosed patients, with substantial underdiagnosis and geographic treatment variation.[1] The commercial opportunity depends less on large epidemiological expansion than on increasing diagnosis, moving untreated patients into prophylaxis, and taking share from injectable therapies.
Main competitive products
| Product |
Company |
Mechanism |
Route |
Primary role |
| Orladeyo |
BioCryst |
Plasma kallikrein inhibitor |
Oral daily |
Routine prophylaxis |
| Takhzyro |
Takeda |
Plasma kallikrein inhibitor |
Subcutaneous |
Routine prophylaxis |
| Haegarda |
CSL Behring |
C1 esterase inhibitor |
Subcutaneous |
Routine prophylaxis |
| Cinryze |
Takeda |
C1 esterase inhibitor |
Intravenous |
Routine prophylaxis |
| Berinert |
CSL Behring |
C1 esterase inhibitor |
Intravenous |
Acute treatment |
| Firazyr |
Takeda |
Bradykinin B2 receptor antagonist |
Subcutaneous |
Acute treatment |
| Ruconest |
Pharming |
Recombinant C1 esterase inhibitor |
Intravenous |
Acute treatment |
Orladeyo competes most directly with Takhzyro in prophylaxis. Firazyr, Berinert, and Ruconest address acute attacks and are therefore complementary rather than direct substitutes.
What has been the financial trajectory of Orladeyo?
Orladeyo has become BioCryst’s dominant commercial asset. Revenue growth accelerated as the company expanded reimbursement, increased prescriber adoption, and commercialized the product across additional countries.
| Year |
Orladeyo reported revenue |
Approximate year-over-year growth |
| 2020 |
Limited launch revenue |
Initial U.S. launch in December |
| 2021 |
$65.8 million |
Not comparable to full prior year |
| 2022 |
$160.5 million |
144% |
| 2023 |
$348.7 million |
117% |
| 2024 |
Approximately $500 million |
Approximately 40% |
Sources: BioCryst annual reports and earnings disclosures.[1-4]
The trajectory shows a transition from launch-stage commercialization to a scaled specialty-pharmaceutical franchise. Revenue growth after 2023 remained strong in absolute terms, although the percentage growth rate moderated as the product base increased.
Revenue drivers
The main revenue drivers are:
- New patient starts in the United States.
- Conversion from injectable prophylaxis.
- Improved reimbursement and specialty-pharmacy access.
- International launches and distributor expansion.
- Pediatric use in patients at least 12 years old.
- Higher persistence associated with once-daily oral dosing.
BioCryst has linked Orladeyo growth to increased patient identification and diagnosis, rather than relying only on price increases. That supports a longer commercial runway but also leaves the product exposed to payer restrictions and competition in the same prophylaxis segment.[1-4]
When does Orladeyo lose U.S. exclusivity?
Orladeyo received U.S. approval on December 3, 2020. It also received orphan-drug designation for hereditary angioedema.
| Protection type |
Relevant date or period |
Commercial effect |
| FDA approval |
December 3, 2020 |
Start of U.S. commercial approval |
| New chemical entity exclusivity |
Five years from approval, subject to statutory rules |
Blocks certain ANDA approvals during the period |
| Orphan-drug exclusivity |
Seven years from approval |
Protects the approved orphan indication |
| Patent protection |
Extends beyond regulatory exclusivity through listed and related patent rights |
May delay generic launch after regulatory exclusivity |
The seven-year orphan-drug exclusivity period is generally the most important regulatory barrier for the approved hereditary angioedema indication, placing the relevant endpoint in December 2027, subject to statutory exceptions and any applicable pediatric extension.[5-7]
Regulatory exclusivity and patent protection are separate. A generic applicant could pursue a filing strategy after the relevant regulatory barriers expire while challenging listed patents through Paragraph IV certification.
What patents protect berotralstat and Orladeyo?
Orladeyo’s U.S. protection is based on a combination of compound, pharmaceutical composition, formulation, and use-related rights. The most commercially relevant patent categories are:
Compound and composition patents
These claims protect berotralstat or pharmaceutical compositions containing berotralstat. Compound claims generally create the strongest barrier because a competing product cannot avoid infringement merely by changing excipients or tablet characteristics.
Formulation patents
Formulation claims may cover the oral dosage form, excipient system, stability profile, release characteristics, or other product attributes. These patents can be important against generic tablets that use the same active ingredient but adopt a different formulation strategy.
Method-of-use patents
Use claims may cover the administration of berotralstat for prophylaxis of hereditary angioedema attacks, including patient populations, dosing regimens, or treatment settings. Their practical value depends on claim scope, labeling, induced-infringement theories, and the ability of a generic applicant to use a narrower label.
The effective generic-entry date will depend on the combined strength and expiration dates of the Orange Book-listed patents, non-listed patent rights, orphan exclusivity, and any litigation settlement. Patent-term adjustment, patent-term extension, pediatric exclusivity, and litigation outcomes can change the practical entry date.[6-8]
What is the Orange Book status of Orladeyo?
Orladeyo is an FDA-approved small-molecule drug, so the relevant generic pathway is an abbreviated new drug application rather than a biosimilar application. FDA Orange Book listings are therefore central to any U.S. generic challenge.
A prospective generic applicant would typically review:
- Listed patents covering the active ingredient or product.
- Expiration dates and remaining patent term.
- Whether a Paragraph IV certification is commercially viable.
- Whether a section viii labeling carve-out could avoid method-of-use claims.
- The effect of orphan exclusivity on approval timing.
- Possible 30-month litigation stays under the Hatch-Waxman framework.
No biosimilar risk exists for berotralstat because it is a chemically synthesized small molecule. The relevant long-term threat is an ANDA-based generic challenge.
Which companies are challenging Orladeyo?
Publicly visible market competition has centered on branded hereditary angioedema therapies rather than a confirmed commercial generic launch. The main competitive pressure comes from Takeda’s Takhzyro and established C1 esterase inhibitor products.
A generic entrant would likely target the following vulnerabilities:
- High annual treatment cost.
- Stable, well-characterized oral dosage form.
- Large enough U.S. revenue base to support patent litigation.
- Expiration of regulatory exclusivity after 2027.
- Potential ability to design around method-of-use or formulation claims.
BioCryst’s response has been to expand international access, support adherence, broaden prescriber use, and develop additional hereditary angioedema assets. The company’s sebetralstat program is designed for acute attack treatment and would complement Orladeyo rather than directly replace its prophylaxis indication.
What FDA and international regulatory milestones affect the market?
The U.S. approval in December 2020 established Orladeyo as an oral prophylactic option for hereditary angioedema. Subsequent regulatory expansion into additional jurisdictions increased the addressable commercial market.
Key regulatory factors include:
- U.S. approval for routine prophylaxis in patients age 12 and older.
- Orphan-drug status in the United States.
- International approvals and reimbursement decisions.
- Pediatric-label expansion as evidence and regulatory requirements develop.
- Manufacturing and supply-chain compliance for global distribution.
- Competitive approvals for other kallikrein inhibitors.
Regulatory expansion supports revenue growth but does not guarantee reimbursement. In many markets, hereditary angioedema therapies are subject to specialist prescribing, prior authorization, national tendering, or hospital-based purchasing.
How strong is the commercial patent estate for berotralstat?
The commercial estate is strongest during the period when compound or composition patents overlap with orphan exclusivity and high branded revenue. Its practical strength declines if:
- Core composition claims expire before secondary patents.
- Generic applicants can use a section viii carve-out.
- Formulation claims are narrow.
- Patent litigation produces invalidity or non-infringement findings.
- Competitors establish therapeutic interchangeability or superior convenience.
The product has a favorable commercial profile because oral administration creates a clear patient-value proposition. That value does not eliminate patent risk, but it may support continued branded use after the first generic entry if BioCryst maintains physician and patient preference.
What generic entry risks exist for Orladeyo?
The most likely U.S. entry scenarios are:
| Scenario |
Timing |
Market effect |
| No successful Paragraph IV challenge |
After regulatory and patent barriers expire |
Later, potentially orderly erosion |
| Early Paragraph IV settlement |
Before patent expiration |
Entry date negotiated with BioCryst |
| Successful invalidity or non-infringement challenge |
Before listed patent expiry |
Earlier generic launch and rapid price pressure |
| Single generic launch |
First year after entry |
Moderate initial erosion, depending on substitution |
| Multiple generic launches |
Later period |
Faster price compression and payer-led conversion |
Orphan exclusivity could delay approval for a generic seeking the same orphan indication until late 2027, but it would not necessarily prevent all off-label or differently labeled strategies after the applicable statutory period. Patent litigation and settlement terms will determine the practical timing.
How does Orladeyo compare with Takhzyro?
| Factor |
Orladeyo |
Takhzyro |
| Active ingredient |
Berotralstat |
Lanadelumab |
| Mechanism |
Plasma kallikrein inhibition |
Plasma kallikrein inhibition |
| Administration |
Oral once daily |
Subcutaneous injection at extended intervals |
| Main commercial advantage |
Avoids injections |
Less frequent dosing |
| Main risk |
Daily adherence and generic exposure |
Injection burden and competing oral therapy |
| Manufacturer |
BioCryst |
Takeda |
| Market role |
Prophylaxis |
Prophylaxis |
Orladeyo has a route-of-administration advantage. Takhzyro has a dosing-frequency advantage. The competitive outcome will depend on patient preference, attack control, reimbursement, physician familiarity, and the relative persistence of patients on each therapy.
What is the long-term revenue outlook for Orladeyo?
Orladeyo has a credible path to continued growth through international expansion, patient diagnosis, prophylaxis penetration, and switching from injectable therapies. Its revenue base is large enough to support meaningful value creation for BioCryst but also large enough to attract generic and branded competition.
The central financial risks are:
- Slower diagnosis of hereditary angioedema.
- Payer pressure on specialty-drug pricing.
- Loss of patients to Takhzyro or future oral inhibitors.
- Generic entry after the exclusivity period.
- Manufacturing or supply interruptions.
- Concentration of BioCryst revenue in one commercial product.
The central upside factors are:
- Broader global reimbursement.
- Higher prophylaxis adoption.
- Expansion into younger patients.
- Persistent patient preference for oral dosing.
- Portfolio leverage from complementary acute-treatment products.
Key Takeaways
- Orladeyo is BioCryst’s principal commercial product and the company’s financial engine.
- Reported revenue rose from $65.8 million in 2021 to $348.7 million in 2023 and approximately $500 million in 2024.
- The product competes directly with Takhzyro and indirectly with C1 esterase inhibitor therapies.
- U.S. orphan-drug exclusivity places the principal regulatory protection endpoint in December 2027, subject to applicable statutory extensions and exceptions.
- Berotralstat faces generic, not biosimilar, risk.
- The key patent issues involve compound, composition, formulation, and method-of-use claims.
- Oral once-daily administration is the primary commercial differentiator.
- The financial trajectory remains growth-oriented, but future valuation depends on international expansion and the timing of generic entry.
FAQs
Is berotralstat dihydrochloride the same as Orladeyo?
Yes. Berotralstat dihydrochloride is the active pharmaceutical ingredient in Orladeyo, BioCryst’s branded oral prophylactic treatment for hereditary angioedema.
Is Orladeyo approved for acute hereditary angioedema attacks?
No. Orladeyo is approved for routine prevention. Acute attacks require an on-demand therapy such as icatibant, plasma-derived C1 esterase inhibitor, recombinant C1 esterase inhibitor, or another approved acute-treatment product.
Can a generic manufacturer launch berotralstat before 2027?
A generic manufacturer could challenge patents before 2027 through Paragraph IV certification, but approval and launch would be affected by orphan exclusivity, listed patents, litigation, and any settlement with BioCryst.
What is the biggest commercial advantage of Orladeyo?
Its principal advantage is oral once-daily administration, which avoids the injections or infusions required by many competing prophylactic therapies.
Does BioCryst depend heavily on Orladeyo revenue?
Yes. Orladeyo represents the substantial majority of BioCryst’s commercial revenue, making product growth, pricing, supply, and exclusivity central to the company’s financial outlook.
References
- BioCryst Pharmaceuticals, Inc. (2022). 2021 annual report on Form 10-K. U.S. Securities and Exchange Commission.
- BioCryst Pharmaceuticals, Inc. (2023). 2022 annual report on Form 10-K. U.S. Securities and Exchange Commission.
- BioCryst Pharmaceuticals, Inc. (2024). 2023 annual report on Form 10-K. U.S. Securities and Exchange Commission.
- BioCryst Pharmaceuticals, Inc. (2025). 2024 annual report and full-year financial disclosures.
- U.S. Food and Drug Administration. (2020). Orladeyo prescribing information.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Food and Drug Administration. (2024). Orphan drug designation and exclusivity provisions.
- U.S. Patent and Trademark Office. (2024). Patent term adjustment and patent term extension guidance.
